LONDON and CHICAGO, IL--(MARKET WIRE)--Jun 3, 2007 -- Antisoma plc (LSE: ASM, US OTC: ATSMY) announces the presentation today at ASCO of new, positive data from its randomised phase II trial testing the addition of ASA404 (formerly AS1404) to first-line docetaxel chemotherapy in hormone-refractory prostate cancer.
